Liver X receptor activation induces apoptosis of melanoma cell through caspase pathway

Cancer Cell International

Xiangbin Yuan¹  Zihao Lin¹  Xiaohai Zhu¹  Yaozhong Zhao¹  Antang Liu¹  Yinfan Zhang¹  Jianlin Zhang¹  Hua Jiang¹  Wenjun Zhang¹ 

[1] Department of Plastic Surgery, Changzheng Hospital, 18F, No. 415 Fengyang Road, Shanghai, China

关键词: T0901317;    Melanoma;    Liver X receptor;   

Others  :  792327
DOI  :  10.1186/1475-2867-14-16

 received in 2013-09-11, accepted in 2014-02-20,  发布年份 2014

【 摘 要 】

Liver X receptors (LXRs) are nuclear receptors that function as ligand-activated transcription factors regulating lipid metabolism and inflammation. Recent discoveries found LXRs could regulate tumor growth in a variety of cancer cell lines. In this study, we investigated the effect of LXR activation on melanoma cell proliferation and apoptosis both in vitro and in vivo. Treatment of B16F10 and A-375 melanoma cells with synthetic LXR agonist T0901317 significantly inhibited the proliferation of melanoma cells in vitro. Meanwhile, T0901317 induced the apoptosis of B16F10 melanoma cells in a dose-dependent manner. Furthermore, western blot assay showed that the pro-apoptotic effect of T0901317 on B16F10 melanoma cells was mediated through caspase-3 pathway. Oral administration of T0901317 inhibited the growth of B16F10 melanoma in C56BL/6 mice. Altogether, this study demonstrates the critical role of LXRs in the regulation of melanoma growth and presents the LXR agonist T0901317 as a potential anti-melanoma agent.

【 授权许可】

   
2014 Zhang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Ko JM, Fisher DE: A new era: melanoma genetics and therapeutics. J Pathol 2011, 223(2):241-250.
• [2]Felli N, Felicetti F, Lustri AM, Errico MC, Bottero L, Cannistraci A, De Feo A, Petrini M, Pedini F, Biffoni M, Alvino E, Negrini M, Ferracin M, Mattia G, Carè A: miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma. PloS One 2013, 8(2):e56824.
• [3]Lo Sasso G, Bovenga F, Murzilli S, Salvatore L, Di Tullio G, Martelli N, D'Orazio A, Rainaldi S, Vacca M, Mangia A, Palasciano G, Moschetta A: Liver X receptors inhibit proliferation of human colorectal cancer cells and growth of intestinal tumors in mice. Gastroenterology 2013, 144(7):1497-1507.
• [4]Chuu CP, Kokontis JM, Hiipakka RA, Liao S: Modulation of liver X receptor signaling as novel therapy for prostate cancer. Br J Biomed Sci 2007, 14(5):543-553.
• [5]Collins JL, Fivush AM, Watson MA, Galardi CM, Lewis MC, Moore LB, Parks DJ, Wilson JG, Tippin TK, Binz JG, Plunket KD, Morgan DG, Beaudet EJ, Whitney KD, Kliewer SA, Willson TM: Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. Eur J Med Chem 2002, 45(10):1963-1966.
• [6]Peng D, Hiipakka RA, Dai Q, Guo J, Reardon CA, Getz GS, Liao S: Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice. J Pharmacol Exp Ther 2008, 327(2):332-342.
• [7]Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, Lustig KD, Shan B: Role of LXRs in control of lipogenesis. Genes Dev 2000, 14(22):2831-2838.
• [8]Raina A, Kaul D: LXR-alpha genomics programmes neuronal death observed in Alzheimer's disease. Apoptosis 2010, 15(12):1461-1469.
• [9]Chuu CP, Lin HP: Antiproliferative effect of LXR agonists T0901317 and 22(R)-hydroxycholesterol on multiple human cancer cell lines. Anticancer Res 2010, 30(9):3643-3648.
• [10]Fukuchi J, Kokontis JM, Hiipakka RA, Chuu CP, Liao S: Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells. Cancer Res 2004, 64(21):7686-7689.
• [11]Pommier AJ, Alves G, Viennois E, Bernard S, Communal Y, Sion B, Marceau G, Damon C, Mouzat K, Caira F, Baron S, Lobaccaro JM: Liver X Receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells. Oncogene 2010, 29(18):2712-2723.
• [12]Johnson DB, Sosman JA: Update on the targeted therapy of melanoma. Curr Treat Options Oncol 2013, 14(2):280-292.
• [13]Mihic-Probst D, Beer M: [Insights into melanoma from a pathologist's perspective]. Praxis 2013, 102(4):219-224.
• [14]Jakobsson T, Treuter E, Gustafsson JA, Steffensen KR: Liver X receptor biology and pharmacology: new pathways, challenges and opportunities. Trends Pharmacol Sci 2012, 33(7):394-404.
• [15]Collins JL: Therapeutic opportunities for liver X receptor modulators. Curr Opin Drug Discov Devel 2004, 7(5):692-702.
• [16]Man MQ, Choi EH, Schmuth M, Crumrine D, Uchida Y, Elias PM, Holleran WM, Feingold KR: Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processing. J Invest Dermatol 2006, 126(2):386-392.
• [17]Chang KC, Shen Q, Oh IG, Jelinsky SA, Jenkins SF, Wang W, Wang Y, LaCava M, Yudt MR, Thompson CC, Freedman LP, Chung JH, Nagpal S: Liver X receptor is a therapeutic target for photoaging and chronological skin aging. Mol Endocrinol 2008, 22(11):2407-2419.
• [18]Hong I, Lee MH, Na TY, Zouboulis CC, Lee MO: LXRalpha enhances lipid synthesis in SZ95 sebocytes. J Invest Dermatol 2008, 128(5):1266-1272.
• [19]Kumar R, Parsad D, Kaul D, Kanwar AJ: Liver X receptor expression in human melanocytes, does it have a role in the pathogenesis of vitiligo? Exp Dermatol 2010, 19(1):62-64.
• [20]Lee CS, Park M, Han J, Lee JH, Bae IH, Choi H, Son ED, Park YH, Lim KM: Liver X receptor activation inhibits melanogenesis through the acceleration of ERK-mediated MITF degradation. J Invest Dermatol 2013, 133(4):1063-1071.